For the full year, that translated into $175.2 billion in revenue for Elevance (a 2.9% increase over 2023), while profit hit $5.98 billion, almost identical to its total a year ago. Operating revenue ...
Barclays raised the firm’s price target on Elevance Health (ELV) to $512 from $501 and keeps an Overweight rating on the shares post the Q4 ...
Elevance Health, Inc. (NYSE: ELV) reported fourth quarter and full year 2024 results. "As part of our commitment to elevating whole health and advancing health beyond ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback